Search our Database of Scientific Publications and Authors

I’m looking for a

    14199 results match your criteria Annals of the Rheumatic Diseases[Journal]

    1 OF 284

    The value of (18)F-FDG-PET/CT in identifying the cause of fever of unknown origin (FUO) and inflammation of unknown origin (IUO): data from a prospective study.
    Ann Rheum Dis 2017 Sep 19. Epub 2017 Sep 19.
    Department of Internal Medicine 3, Institute for Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum, Erlangen, Germany.
    Background: Fever of unknown origin (FUO) and inflammation of unknown origin (IUO) are diagnostically challenging conditions. Diagnosis of underlying disease may be improved by (18)F-fluorodesoxyglucose positron emission tomography ((18)F-FDG-PET).

    Methods: Prospective study to test diagnostic utility of (18)F-FDG-PET/CT in a large cohort of patients with FUO or IUO and to define parameters that increase the likelihood of diagnostic (18)F-FDG-PET/CT. Read More

    The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy.
    Ann Rheum Dis 2017 Sep 19. Epub 2017 Sep 19.
    Department of Rheumatology, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France.
    The rapid introduction of immunotherapies for cancer-targeting immunological checkpoints has led to a new class of toxicities that appear to be of autoimmune and or autoinflammatory origin. These disorders are now referred to as immune-related adverse events (irAEs) and pose considerable challenges to patient care in terms of how to optimally manage these formidable toxicities while allowing effective antitumoural therapy to continue. While rheumatologists will naturally be called on to manage those irAEs of rheumatic origin, we believe there is a need and an opportunity for rheumatologists to participate as central figures in this evolving field, in large part because of our familiarity with multiorgan autoimmune disease and our expertise in crafting and utilising both traditional and biological immune-based therapies. Read More

    Deregulation of microRNA expression in purified T and B lymphocytes from patients with primary Sjögren's syndrome.
    Ann Rheum Dis 2017 Sep 15. Epub 2017 Sep 15.
    Laboratory for Epigenetics & Environment, Centre National de Recherche en Génomique Humaine - CEA - Institut de Biologie Francois Jacob, Evry, France.
    Objective: MicroRNAs (miRNAs) play an important role in the pathogenesis of autoimmune diseases such as primary Sjögren's syndrome (pSS). This study is the first to investigate miRNA expression patterns in purified T and B lymphocytes from patients with pSS using a high-throughput quantitative PCR (qPCR) approach.

    Methods: Two independent cohorts of both patients with pSS and controls, one for discovery and one for replication, were included in this study. Read More


    Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis.
    Ann Rheum Dis 2017 Sep 15. Epub 2017 Sep 15.
    Centre for Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow, UK.
    Objectives: Patients with rheumatoid arthritis (RA) have reduced serum low-density lipoprotein cholesterol (LDL-c), which increases following therapeutic IL-6 blockade. We aimed to define the metabolic pathways underlying these lipid changes.

    Methods: In the KALIBRA study, lipoprotein kinetic studies were performed on 11 patients with severe active RA at baseline and following three intravenous infusions of the IL-6R blocker tocilizumab. Read More


    Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis.
    Ann Rheum Dis 2017 Sep 6. Epub 2017 Sep 6.
    Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.
    Objectives: Patients with rheumatoid arthritis (RA) have an excess risk of cardiovascular disease (CVD). We aimed to assess the impact of CVD risk factors, including potential sex differences, and RA-specific variables on CVD outcome in a large, international cohort of patients with RA.

    Methods: In 13 rheumatology centres, data on CVD risk factors and RA characteristics were collected at baseline. Read More

    European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative.
    Ann Rheum Dis 2017 Sep 6. Epub 2017 Sep 6.
    Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, The Netherlands.
    Lupus nephritis (LN) occurs in 50%-60% of patients with childhood-onset systemic lupus erythematosus (cSLE), leading to significant morbidity. Timely recognition of renal involvement and appropriate treatment are essential to prevent renal damage. The Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative aimed to generate diagnostic and management regimens for children and adolescents with rheumatic diseases including cSLE. Read More

    Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies.
    Ann Rheum Dis 2017 Sep 2. Epub 2017 Sep 2.
    The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.
    Objectives: Weight loss is commonly recommended for gout, but the magnitude of the effect has not been evaluated in a systematic review. The aim of this systematic review was to determine benefits and harms associated with weight loss in overweight and obese patients with gout.

    Methods: We searched six databases for longitudinal studies, reporting the effect of weight loss in overweight/obese gout patients. Read More

    Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases.
    Ann Rheum Dis 2017 Sep 2. Epub 2017 Sep 2.
    Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
    The study aimed to develop evidence-based recommendations regarding the evaluation and use of biosimilars to treat rheumatological diseases. The task force comprised an expert group of specialists in rheumatology, dermatology and gastroenterology, and pharmacologists, patients and a regulator from ten countries. Four key topics regarding biosimilars were identified through a process of discussion and consensus. Read More

    Chemotaxis of Vδ2 T cells to the joints contributes to the pathogenesis of rheumatoid arthritis.
    Ann Rheum Dis 2017 Sep 2. Epub 2017 Sep 2.
    Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Clinical Immunology Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Ministry of Education Key Laboratory, Beijing, China.
    Objectives: To explore the role of Vδ2 T cells in the pathogenesis of rheumatoid arthritis (RA).

    Methods: Sixty-eight patients with RA, 21 patients with osteoarthritis and 21 healthy controls were enrolled in the study. All patients with RA fulfilled the 2010 American College of Rheumatology/European League Against Rheumatism criteria for RA. Read More

    Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohort.
    Ann Rheum Dis 2017 Sep 2. Epub 2017 Sep 2.
    GRC-UPMC 08, Institut Pierre Louis d'Epidémiologie et Santé Publique, Pierre et Marie Curie University, Paris, France.
    Background: Although methotrexate (MTX) is the consensual first-line disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis (RA), substantial heterogeneity remains with its prescription and dosage, which are often not optimal.

    Objective: To evaluate the symptomatic and structural impact of optimal MTX dose in patients with early RA in daily clinical practice over 2 years.

    Methods: Patients included in the early arthritis ESPOIR cohort who fulfilled the ACR-EULAR (American College of Rheumatology/European League against Rheumatism) criteria for RA and received MTX as a first DMARD were assessed. Read More

    Infections and respiratory tract disease as risk factors for idiopathic inflammatory myopathies: a population-based case-control study.
    Ann Rheum Dis 2017 Aug 30. Epub 2017 Aug 30.
    Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
    Objectives: To investigate the association between infection or respiratory tract disease and future risk of developing idiopathic inflammatory myopathy (IIM).

    Methods: A case-control study was performed using Swedish nationwide registers. Adults with newly diagnosed IIM were identified (2002-2011) from the National Patient Register (NPR) and the Swedish Rheumatology Register (n=957). Read More

    The EuroMyositis registry: an international collaborative tool to facilitate myositis research.
    Ann Rheum Dis 2017 Aug 30. Epub 2017 Aug 30.
    Department of Rheumatology, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, UK.
    Aims: The EuroMyositis Registry facilitates collaboration across the idiopathic inflammatory myopathy (IIM) research community. This inaugural report examines pooled Registry data.

    Methods: Cross-sectional analysis of IIM cases from 11 countries was performed. Read More

    Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study.
    Ann Rheum Dis 2017 Aug 30. Epub 2017 Aug 30.
    GlaxoSmithKline Research and Development, Stevenage, Hertfordshire, UK.
    Objectives: Interleukin-6 (IL-6) is implicated in rheumatoid arthritis (RA) pathophysiology. Unlike IL-6 receptor inhibitors, sirukumab is a human monoclonal antibody that selectively binds to the IL-6 cytokine. The phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group SIRROUND-D study (ClinicalTrials. Read More

    Genome-wide association and functional studies identify a role for matrix Gla protein in osteoarthritis of the hand.
    Ann Rheum Dis 2017 Aug 30. Epub 2017 Aug 30.
    Department of Internal Medicine, Genetic Laboratory, Erasmus Medical Center, Rotterdam, The Netherlands.
    Objective: Osteoarthritis (OA) is the most common form of arthritis and the leading cause of disability in the elderly. Of all the joints, genetic predisposition is strongest for OA of the hand; however, only few genetic risk loci for hand OA have been identified. Our aim was to identify novel genes associated with hand OA and examine the underlying mechanism. Read More

    Identification of a transitional fibroblast function in very early rheumatoid arthritis.
    Ann Rheum Dis 2017 Aug 28. Epub 2017 Aug 28.
    Rheumatology Research Group, Arthritis Research UK Centre of Excellence in the Pathogenesis of Rheumatoid Arthritis, Institute of Inflammation and Ageing, Birmingham, UK.
    Objectives: Synovial fibroblasts actively regulate the inflammatory infiltrate by communicating with neighbouring endothelial cells (EC). Surprisingly, little is known about how the development of rheumatoid arthritis (RA) alters these immunomodulatory properties. We examined the effects of phase of RA and disease outcome (resolving vs persistence) on fibroblast crosstalk with EC and regulation of lymphocyte recruitment. Read More

    The effects of structural damage on functional disability in psoriatic arthritis.
    Ann Rheum Dis 2017 Aug 23. Epub 2017 Aug 23.
    Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria.
    Background: Functional outcomes are central in patients with chronic inflammatory musculoskeletal diseases. In a secondary data analysis of the GO-REVEAL trial (NCT00265096), we investigated wether structural damage is linked to functional impairment in patients with psoriatic arthritis (PsA), a link that is still elusive in this disease.

    Methods: We analysed 363 patients enrolled in the GO-REVEAL study and obtained modified Sharp/van der Heijde Scores (mSvdHS) from X-rays performed at baseline, after 24, 52 and 104 weeks. Read More

    Mapping and predicting mortality from systemic sclerosis.
    Ann Rheum Dis 2017 08 23. Epub 2017 Aug 23.
    Rheumatology A department, Paris Descartes University, INSERM U1016, Sorbonne Paris Cité, Cochin Hospital, Paris, France.
    Objectives: To determine the causes of death and risk factors in systemic sclerosis (SSc).

    Methods: Between 2000 and 2011, we examined the death certificates of all French patients with SSc to determine causes of death. Then we examined causes of death and developed a score associated with all-cause mortality from the international European Scleroderma Trials and Research (EUSTAR) database. Read More


    A novel Pyrin-Associated Autoinflammation with Neutrophilic Dermatosis mutation further defines 14-3-3 binding of pyrin and distinction to Familial Mediterranean Fever.
    Ann Rheum Dis 2017 Aug 23. Epub 2017 Aug 23.
    Inflammation Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
    Objective: Pyrin-Associated Autoinflammation with Neutrophilic Dermatosis (PAAND) is a recently described monogenic autoinflammatory disease. The causal p.S242R MEFV mutation disrupts a binding motif of the regulatory 14-3-3 proteins within pyrin. Read More

    Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series.
    Ann Rheum Dis 2017 Aug 22. Epub 2017 Aug 22.
    Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
    Background: Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with numerous cancers. However, these therapies are associated with immune-related adverse events (irAEs), which are inflammatory side effects potentially affecting any organ. Cases of ICI-induced inflammatory arthritis have also been reported. Read More

    Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study.
    Ann Rheum Dis 2017 Aug 22. Epub 2017 Aug 22.
    Department of Medicine, University of Auckland, Auckland, New Zealand.
    Objectives: To determine the long-term safety and efficacy of allopurinol dose escalation (DE) to achieve target serum urate (SU) in gout.

    Methods: People, including those with chronic kidney disease, who completed the first 12 months of a randomised controlled trial continued into a 12-month extension study. Participants randomised to continue current dose for the first 12 months began allopurinol DE at month 12 if SU was ≥6 mg/dL (control/DE). Read More

    Long-term outcomes and secondary prevention after acute coronary events in patients with rheumatoid arthritis.
    Ann Rheum Dis 2017 Aug 20. Epub 2017 Aug 20.
    Department of Medicine Solna, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden.
    Objectives: Patients with rheumatoid arthritis (RA) are at increased risk of acute coronary syndrome (ACS) and suffer from poorer short-term outcomes after ACS. The aims of this study were to assess long-term outcomes in patients with RA with ACS compared with non-RA patients with ACS, and to investigate whether the use of secondary preventive drugs could explain any differences in ACS outcome.

    Methods: We performed a cohort study based on 1135 patients with RA and 3184 non-RA patients who all developed an incident ACS between 2007 and 2010. Read More

    Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project.
    Ann Rheum Dis 2017 Aug 19. Epub 2017 Aug 19.
    Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany.
    Background: Lymphomas comprise a heterogeneous group of malignant diseases with highly variable prognosis. Rheumatoid arthritis (RA) is associated with a twofold increased risk of both Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). It is unknown whether treatment with biologic disease-modifying antirheumatic drugs (bDMARDs) affect the risk of specific lymphoma subtypes. Read More

    Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis.
    Ann Rheum Dis 2017 Oct 18;76(10):1774-1779. Epub 2017 Aug 18.
    Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
    Objectives: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis, with a strong heritable component, affecting patients with psoriasis. Here we attempt to identify genetic variants within the major histocompatibility complex (MHC) that differentiate patients with PsA from patients with cutaneous psoriasis alone (PsC).

    Methods: 2808 patients with PsC, 1945 patients with PsA and 8920 population controls were genotyped. Read More

    B cell OX40L supports T follicular helper cell development and contributes to SLE pathogenesis.
    Ann Rheum Dis 2017 Aug 17. Epub 2017 Aug 17.
    Division of Medical and Molecular Genetics and Immunology, Infection and Inflammatory Disease, King's College London, London, UK.
    Objectives: TNFSF4 (encodes OX40L) is a susceptibility locus for systemic lupus erythematosus (SLE). Risk alleles increase TNFSF4 expression in cell lines, but the mechanism linking this effect to disease is unclear, and the OX40L-expressing cell types mediating the risk are not clearly established. Blockade of OX40L has been demonstrated to reduce disease severity in several models of autoimmunity, but not in SLE. Read More

    Oral contraceptives, breastfeeding and the risk of developing rheumatoid arthritis: results from the Swedish EIRA study.
    Ann Rheum Dis 2017 Aug 17. Epub 2017 Aug 17.
    Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
    Objectives: To study whether oral contraceptive (OC) use or breastfeeding (BF) influence the risk of rheumatoid arthritis (RA), stratifying the cases by presence/absence of anticitrullinated protein antibodies (ACPA), and whether these factors interact with known risk factors in the development of ACPA-positive RA.

    Methods: Women aged ≥18 years, participants in the population-based case-control Swedish Epidemiological Investigation of RA study (2641 cases/4251 controls), completed an extensive questionnaire regarding OC, BF and potential confounders. We calculated ORs, with 95% CIs, adjusted for age, residential area, smoking and alcohol consumption. Read More

    Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study.
    Ann Rheum Dis 2017 Aug 16. Epub 2017 Aug 16.
    Texas Tech University School of Medicine, Amarillo, Texas, USA.
    Background: Women with chronic inflammatory diseases face uncertainty regarding the safety of biologics during breast feeding. CRADLE was the first industry-sponsored study to evaluate certolizumab pegol (CZP) concentrations in human breast milk and estimate average daily infant dose (ADID) of maternal CZP.

    Methods: CRADLE (NCT02154425) was a pharmacokinetic study of lactating mothers receiving CZP. Read More

    Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis.
    Ann Rheum Dis 2017 Aug 16. Epub 2017 Aug 16.
    Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.
    Objectives: Calprotectin is an inflammatory marker of interest in rheumatoid arthritis (RA). We evaluated whether the level of calprotectin was associated with disease activity, and if it was predictive of treatment response and radiographic progression in patients with early RA.

    Methods: Plasma from disease-modifying antirheumatic drug (DMARD)-naïve patients with RA fulfilling 2010 American College of Rheumatology/European League Against Rheumatism classification criteria with symptom duration <2 years was analysed for calprotectin at baseline, and after 1, 3 and 12 months. Read More

    The 2017 EULAR standardised procedures for ultrasound imaging in rheumatology.
    Ann Rheum Dis 2017 Aug 16. Epub 2017 Aug 16.
    Department of Rheumatology, Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz and Autónoma University, Madrid, Spain.
    Background: In 2001, the European League Against Rheumatism developed and disseminated the first guidelines for musculoskeletal (MS) ultrasound (US) in rheumatology. Fifteen years later, the dramatic expansion of new data on MSUS in the literature coupled with technological developments in US imaging has necessitated an update of these guidelines.

    Objectives: To update the existing MSUS guidelines in rheumatology as well as to extend their scope to other anatomic structures relevant for rheumatology. Read More

    Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis.
    Ann Rheum Dis 2017 Aug 16. Epub 2017 Aug 16.
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
    Background: Nintedanib is an inhibitor targeting platelet-derived growth factor receptor, fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases that has recently been approved for the treatment of idiopathic pulmonary fibrosis. The aim of this study was to analyse the effects of nintedanib in the fos-related antigen-2 (Fra2) mouse model of systemic sclerosis (SSc).

    Methods: The effects of nintedanib on pulmonary arterial hypertension with proliferation of pulmonary vascular smooth muscle cells (PVSMCs) and luminal occlusion, on microvascular disease with apoptosis of microvascular endothelial cells (MVECs) and on fibroblast activation with myofibroblast differentiation and accumulation of extracellular matrix were analysed. Read More

    Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study.
    Ann Rheum Dis 2017 Aug 16. Epub 2017 Aug 16.
    Rheumatology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
    Patients with idiopathic inflammatory myopathies (IIMs) suffer an increased burden of comorbidities, but data on mortality in recently diagnosed IIM are conflicting. Also, little is known when, if ever, in relation to IIM diagnosis, mortality is increased.

    Methods: A population-based IIM cohort of patients diagnosed between 2002 and 2011 and general population comparators were identified using healthcare registers. Read More

    Response to: 'The GRAPPA-OMERACT initiative to standardise outcomes in Psoriatic Arthritis clinical trials and longitudinal observational studies' by Tillet et al.
    Ann Rheum Dis 2017 Aug 16. Epub 2017 Aug 16.
    UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), Sorbonne Universités, Paris, France.

    Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension.
    Ann Rheum Dis 2017 Aug 11. Epub 2017 Aug 11.
    Université Paris Descartes, Sorbonne Paris Cité, INSERM U1016, Institut Cochin, CNRS UMR8104, Paris, France.
    Objective: To evaluate the antifibrotic effects of the pan-peroxisome proliferator-activated receptor (PPAR) agonist IVA337 in preclinical mouse models of pulmonary fibrosis and related pulmonary hypertension (PH).

    Methods: IVA337 has been evaluated in the mouse model of bleomycin-induced pulmonary fibrosis and in Fra-2 transgenic mice, this latter being characterised by non-specific interstitial pneumonia and severe vascular remodelling of pulmonary arteries leading to PH. Mice received two doses of IVA337 (30 mg/kg or 100 mg/kg) or vehicle administered by daily oral gavage up to 4 weeks. Read More

    Molecular basis for increased susceptibility of Indigenous North Americans to seropositive rheumatoid arthritis.
    Ann Rheum Dis 2017 Aug 11. Epub 2017 Aug 11.
    The University of Queensland Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Australia.
    Objective: The pathogenetic mechanisms by which HLA-DRB1 alleles are associated with anticitrullinated peptide antibody (ACPA)-positive rheumatoid arthritis (RA) are incompletely understood. RA high-risk HLA-DRB1 alleles are known to share a common motif, the 'shared susceptibility epitope (SE)'. Here, the electropositive P4 pocket of HLA-DRB1 accommodates self-peptide residues containing citrulline but not arginine. Read More

    1 OF 284